The PRMRP Discovery Award is intended to support innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. The proposed project may be exploratory, hypothesis-driven, or hypothesis-generating research but must be novel and must be based on a strong scientific rationale and a well-developed study design and plan of analysis. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation or product development. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for groundbreaking future research projects.
This award is not intended to support/validate ongoing research and inclusion of preliminary data is not allowed. Inclusion of preliminary data other than serendipitous finding is not consistent with the exploratory nature of this award. Applicants seeking funding for research to further an existing research project should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline..
Deadlines:
• Required Pre-Application Deadline: May 6, 2024
• Application Submission Deadline: May 23, 2024
- AUTOIMMUNE DISORDERS AND IMMUNOLOGY
- CARDIOVASCULAR HEALTH
- INFECTIOUS DISEASES
- INTERNAL MEDICINE
- NEUROSCIENCE
- ORTHOPAEDIC MEDICINE
- RARE DISEASES AND CONDITIONS
- RESPIRATORY HEALTH
Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the Principal Investigator (PI) on the application.
Each investigator may be named on only one FY24 PRMRP DA application as a PI.
The anticipated direct costs budgeted for the entire period of performance for an FY24 PRMRP Discovery Award should not exceed $275,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.